15. Genetic Syndromes, Metabolic Storage Diseases, and the Heart
Numerous genetic syndromes and inborn errors of metabolism exhibit distinctive cardiovascular malformations and conduction disturbances that manifest as classic electrocardiographic signatures.
1. Syndromic & Metabolic Electrocardiographic Matrix
| Syndrome / Disorder | Underlying Gene / Defect | Classical Cardiac Lesions | Electrocardiographic Signatures |
|---|---|---|---|
| Down Syndrome (Trisomy 21) | Trisomy 21 | Complete Atrioventricular Canal Defect (AVSD), VSD, ASD. | Left Superior Axis ($-30^\circ \text{ to } -90^\circ$), prolonged PR interval, counterclockwise frontal loop. |
| Turner Syndrome (45,X) | Monosomy X | Bicuspid Aortic Valve, Coarctation of Aorta, Hypoplastic Left Heart. | Severe LVH with strain, early repolarization abnormalities. |
| Noonan Syndrome | $PTPN11, SOS1, RAF1$ | Dysplastic Pulmonary Valve Stenosis, Hypertrophic Cardiomyopathy. | Extreme Right Axis or Northwest Axis, massive RVH, giant $Q$ waves in inferior leads. |
| Williams Syndrome | 7q11.23 microdeletion (Elastin) | Supravalvular Aortic Stenosis, Peripheral Pulmonary Stenosis. | Shortened $QTc$ (infantile hypercalcemia), severe biventricular hypertrophy, RVH. |
| Pompe Disease (GSD Type II) | Acid $\alpha$-glucosidase (GAA) | Massive generalized hypertrophic cardiomyopathy, heart failure. | Massive LVH Voltage ($R+S > 80-100\text{ mm}$) + Extremely Short PR Interval ($<0.08\text{ s}$) without true delta wave. |
| Danon Disease | $LAMP2$ (X-linked) | Severe hypertrophic cardiomyopathy, intellectual disability. | High-voltage LVH + Wolff-Parkinson-White Pre-excitation (frequent accessory pathways). |
| Friedreich Ataxia | Trinucleotide repeat (FXN) | Concentric hypertrophic cardiomyopathy. | Diffuse deep T-wave inversions across lateral/precordial leads, progressive LVH. |
| Holt-Oram Syndrome | $TBX5$ (Heart-Hand syndrome) | Secundum/Primum ASD, VSD, upper limb radial ray defects. | Progressive Atrioventricular Block (1st, 2nd, 3rd degree), junctional rhythms. |
2. Multimodality Diagnostic Investigations
- Enzyme Assay & Metabolic Panels: Dried blood spot acid $\alpha$-glucosidase activity for Pompe disease; serum calcium for Williams syndrome.
- Targeted Genetic Panels: Chromosomal microarray, Next-Generation Sequencing multigene panels.
- Echocardiography: Measures asymmetrical septal thickness Z-scores, outflow tract gradients, and biventricular dimensions.
3. Evidence-Based Clinical Management Protocols
- Enzyme Replacement Therapy (ERT): Recombinant human acid $\alpha$-glucosidase (Alglucosidase alfa / Avalglucosidase alfa) in infantile Pompe disease causes dramatic regression of cardiac hypertrophy and normalization of ECG voltages.
- Surveillance for Conduction System Degeneration: Lifelong annual Holter and ECG monitoring in Holt-Oram syndrome and Friedreich ataxia for prophylactic pacemaker planning.